8-K 1 k71235e8vk.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT: AUGUST 12, 2002 (Date of earliest event reported) GENOMIC SOLUTIONS INC. (Exact name of registrant as specified in its charter) DELAWARE COMMISSION FILE NO. 000-30549 38-3383038 (State of incorporation) (IRS Employer I.D. No.) 4355 VARSITY DRIVE ANN ARBOR, MICHIGAN 48108 (Address of principal executive offices) (734) 975-4800 (Registrant's telephone number, including area code) ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT On August 12, 2002, the Board of Directors of Genomic Solutions Inc. (the "Company") engaged KPMG LLP ("KPMG") to serve as the Company's independent public accountants for the fiscal year 2002. During the years ended December 31, 2001 and 2000 and through the date of the Board's decision, the Company did not consult KPMG with respect to the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's consolidated financial statements, or any other matters or reportable events as set forth in Items 304(a)(2)(i) and (ii) of Regulation S-K. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENOMIC SOLUTIONS INC., a Delaware corporation Date: August 12, 2002 By: /s/ Steven J. Richvalsky --------------------------- Steven J. Richvalsky Its: Executive Vice President and Chief Financial Officer

GENOMIC SOLUTIONS INC 8-K